- Home
- ICUI
ICUI
ICU Medical Inc.
as of 03-10-2026 1:33pm EST
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | SAN CLEMENTE |
| Market Cap: | 3.9B | IPO Year: | 1995 |
| Target Price: | $182.25 | AVG Volume (30 days): | 263.1K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.03 | EPS Growth: | 100.62 |
| 52 Week Low/High: | $107.02 - $160.29 | Next Earning Date: | 05-22-2026 |
| Revenue: | $2,231,262,000 | Revenue Growth: | -6.33% |
| Revenue Growth (this year): | -0.5% | Revenue Growth (next year): | 4.46% |
| P/E Ratio: | 4406.67 | Index: | N/A |
| Free Cash Flow: | 91.8M | FCF Growth: | -26.36% |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 19, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 19, 2026 · 100% conf.
1D
-5.08%
$142.13
5D
-8.04%
$137.70
20D
-4.65%
$142.78
icui-20260219falseICU MEDICAL INC/DE000088398400008839842026-02-192026-02-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 19, 2026
ICU MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3463433-0022692 (State or other jurisdiction of incorporation) (Commission File Number)(IRS Employer Identification No.)
951 Calle Amanecer,San Clemente,California92673 (Address of principal executive offices)(Zip Code)
(949) 366-2183 Registrant's telephone number, including area code
N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC (Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 19, 2026, ICU Medical, Inc. issued a press release announcing its financial results for the fourth quarter of 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in Item 2.02 by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1 Press release, dated February 19, 2026 announcing ICU Medical, Inc.'s fourth quarter 2025 earnings. 104Cover Page Interactive Data File (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ICU MEDICAL, INC.
Date: February 19, 2026 By: /s/ Brian M. Bonnell Brian M. Bonnell Chief Financial Officer and Treasurer
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
Q3 2025 Earnings
8-KNov 6, 2025
icui-20251106falseICU MEDICAL INC/DE000088398400008839842025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 6, 2025
ICU MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3463433-0022692 (State or other jurisdiction of incorporation) (Commission File Number)(IRS Employer Identification No.)
951 Calle Amanecer,San Clemente,California92673 (Address of principal executive offices)(Zip Code)
(949) 366-2183 Registrant's telephone number, including area code
N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC (Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On November 6, 2025, ICU Medical, Inc. issued a press release announcing its financial results for the third quarter of 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in Item 2.02 by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1 Press release, dated November 6, 2025 announcing ICU Medical, Inc.'s third quarter 2025 earnings. 104Cover Page Interactive Data File (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ICU MEDICAL, INC.
Date: November 6, 2025 By: /s/ Brian M. Bonnell Brian M. Bonnell Chief Financial Officer and Treasurer
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
Q2 2025 Earnings
8-KAug 7, 2025
icui-20250807falseICU MEDICAL INC/DE000088398400008839842025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 7, 2025
ICU MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3463433-0022692 (State or other jurisdiction of incorporation) (Commission File Number)(IRS Employer Identification No.)
951 Calle Amanecer,San Clemente,California92673 (Address of principal executive offices)(Zip Code)
(949) 366-2183 Registrant's telephone number, including area code
N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC (Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On August 7, 2025, ICU Medical, Inc. issued a press release announcing its financial results for the second quarter of 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in Item 2.02 by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1 Press release, dated August 7, 2025 announcing ICU Medical, Inc.'s second quarter 2025 earnings. 104Cover Page Interactive Data File (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ICU MEDICAL, INC.
Date: August 7, 2025 By: /s/ Brian M. Bonnell Brian M. Bonnell Chief Financial Officer and Treasurer
Compare ICUI vs Leading Stocks
See how ICUI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ICUI ICU Medical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.